Moderna Inc. stock: Brookline cuts FY2030 EPS estimate pre-market
Published on 10/26/2026 at 08:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst estimate and market context
- Brookline Capital Markets lowered its FY2030 earnings estimate to USD 18.19 from USD 19.11 in a report released on October 22, 2026.
- Moderna's home exchange is Nasdaq, as identified in MarketBeat's October 26, 2026 report.
- Moderna Inc. stock trades pre-market at EUR 173.84 at 8:12 a.m. CET at Lang & Schwarz on October 26, 2026.
MarketBeat reported on October 26, 2026, that Brookline Capital Markets lowered its Moderna FY2030 earnings estimate in a report released on October 22. The analyst now expects USD 18.19 per share, compared with a previous estimate of USD 19.11, while retaining a Buy rating. The report identifies Moderna's listing as Nasdaq.
Analyst estimate
The estimate change is the latest company-specific analyst item identified for the stock. It concerns Brookline Capital Markets' FY2030 earnings forecast and does not represent reported Moderna financial results.
Ahead of the Xetra open
The further course from the Xetra open at 9:00 a.m. CET is shown by the continuously updated real-time quote of Moderna Inc. stock.
Moderna and its business
Moderna develops medicines and vaccines using messenger RNA technology, with programs spanning infectious diseases, immuno-oncology, rare diseases and autoimmune conditions, according to the company's website.
Market context: Market report S&P 500.
